CSIMarket



Biogen Inc   (BIIB)
Other Ticker:  
 
 

BIIB's Income from Cont. Operations Growth by Quarter and Year

Biogen Inc 's Income from Cont. Operations results by quarter and year




BIIB Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -20.60 357.50 1,439.70
III Quarter September - 318.10 703.90 1,545.90
II Quarter June - 1,025.50 1,606.50 1,494.10
I Quarter March 218.50 404.60 1,392.60 1,408.80
FY   218.50 1,727.60 4,060.50 5,888.50



BIIB Income from Cont. Operations first quarter 2022 Y/Y Growth Comment
Biogen Inc reported drop in Income from Cont. Operations in the first quarter 2022 by -46% to $ 218.50 millions, from the same quarter in 2021.
The fall in the first quarter 2022 Biogen Inc 's Income from Cont. Operations compares unfavorably to the Company's average Income from Cont. Operations increase of 10.89%.

Looking into first quarter 2022 results within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Income from Cont. Operations growth. While Biogen Inc ' s Income from Cont. Operations meltdown of -46% ranks overall at the positon no. 756 in the first quarter 2022.




BIIB Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - -75.17 % 52.37 %
III Quarter September - -54.81 % -54.47 % 7.14 %
II Quarter June - -36.17 % 7.52 % 63.29 %
I Quarter March -46 % -70.95 % -1.15 % 20.29 %
FY   - -57.45 % -31.04 % 31.62 %

Financial Statements
Biogen Inc 's first quarter 2022 Income from Cont. Operations $ 218.50 millions BIIB's Income Statement
Biogen Inc 's first quarter 2021 Income from Cont. Operations $ 404.60 millions Quarterly BIIB's Income Statement
New: More BIIB's historic Income from Cont. Operations Growth >>


BIIB Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - -49.21 % -6.87 %
III Quarter September - -68.98 % -56.18 % 3.47 %
II Quarter June - 153.46 % 15.36 % 6.05 %
I Quarter March - 13.17 % -3.27 % 49.1 %
FY (Year on Year)   - -57.45 % -31.04 % 31.62 %




Income from Cont. Operations first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #56
Overall #756

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
413.15 % 10.89 % -86.75 %
(Sep. 30, 2006)   (June 30. 2006)
Income from Cont. Operations first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #56
Overall #756
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
413.15 % 10.89 % -86.75 %
(Sep. 30, 2006)   (June 30. 2006)

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Biogen Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
4345.95 % 76.43 % -68.98 %
(Sep. 30, 2004)  


BIIB's I. Quarter Q/Q Income from Cont. Operations Comment
I. Quarter 2022Periodic Biogen Inc in the circumstances loss from continued operations of $ 218.50 millionsPeriodic circumstances appear to have contributed Biogen Inc 's restoration of profitability, as BIIB clinchesIncome from Cont. Operations of $ 218.50 millions in the I. Quarter 2022 emanate loss from continued operations-20.60 millions in the forth quarter. Biogen Inc announced in the I. Quarter 2022 Income from Cont. Operations of $ 218.50 millions compare to loss from continued operations recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry Biogen Inc achieved highest sequential Income from Cont. Operations growth. While Biogen Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 0.


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #0
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #0
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
4345.95 % 76.43 % -68.98 %
(Sep. 30, 2004)  


BIIB's I. Quarter Q/Q Income from Cont. Operations Comment
I. Quarter 2022Cyclical Biogen Inc in the circumstances loss from continued operations of $ 218.50 millionsCyclical circumstances seem to have contributed Biogen Inc 's restoration of profitability, as BIIB postIncome from Cont. Operations of $ 218.50 millions in the I. Quarter 2022 emanate loss from continued operations-20.60 millions in the forth quarter. Biogen Inc announced in the I. Quarter 2022 Income from Cont. Operations of $ 218.50 millions compare to loss from continued operations recorded in previos quarter.

Within Biotechnology & Pharmaceuticals industry Biogen Inc achieved highest sequential Income from Cont. Operations growth. While Biogen Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is 0.


Biogen Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ 1,541.50 $ 1,727.60 $ 2,105.70 $ 2,491.50 $ 3,072.50
Y / Y Income from Cont. Operations Growth (TTM) -49.83 % -57.45 % -59.05 % -58.37 % -47.68 %
Year on Year Income from Cont. Operations Growth Overall Ranking # 737 # 268 # 60 # 1829 # 1524
Seqeuential Income from Cont. Operations Change (TTM) -10.77 % -17.96 % -15.48 % -18.91 % -24.33 %
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # 756 # 2046 # 70 # 396 # 138




Cumulative Income from Cont. Operations growth Comment
Biogen Inc showed decline, but improvement compare to trailing twelve month Income from Cont. Operations decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Biogen Inc 's annual Income from Cont. Operations fall would be -49.83% year on year to $1,542 millions.

In the Healthcare sector 53 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Income from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 268 to 737.

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
413.15 %
10.89 %
-86.75 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 54
Overall # 737

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
1760.54 %
57.8 %
-78.16 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 56
S&P 500 # 756
Cumulative Income from Cont. Operations growth Comment
Biogen Inc showed decline, but improvement compare to trailing twelve month Income from Cont. Operations decrease in Dec 31 2021. If the fiscal year would end in Mar 31 2022, Biogen Inc 's annual Income from Cont. Operations drop would be -49.83% year on year to $1,542 millions.

In the Healthcare sector 53 other companies have achieved higher trailing twelve month Income from Cont. Operations growth. While Income from Cont. Operations growth total ranking has deteriorated compare to previous quarter from 268 to 737.

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
413.15 %
10.89 %
-86.75 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 54
Overall # 737

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
1760.54 %
57.8 %
-78.16 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 56
S&P 500 # 756




Other Income from Cont. Operations Growth
Biotechnology & Pharmaceuticals Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
BIIB's Income from Cont. Operations Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for BIIB's Competitors
Income from Cont. Operations Growth for Biogen Inc 's Suppliers
Income from Cont. Operations Growth for BIIB's Customers

You may also want to know
BIIB's Annual Growth Rates BIIB's Profitability Ratios BIIB's Asset Turnover Ratio BIIB's Dividend Growth
BIIB's Roe BIIB's Valuation Ratios BIIB's Financial Strength Ratios BIIB's Dividend Payout Ratio
BIIB's Roa BIIB's Inventory Turnover Ratio BIIB's Growth Rates BIIB's Dividend Comparisons



Companies with similar Income from Cont. Operations drop for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Mar 31 2022
Chemed Corporation-1.88%$ -1.882 millions
Biomx Inc -2.77%$ -2.773 millions
Ironwood Pharmaceuticals inc -2.82%$ -2.818 millions
Corcept Therapeutics Inc-2.85%$ -2.847 millions
Msa Safety Inc-2.89%$ -2.891 millions
Merit Medical Systems Inc-3.77%$ -3.769 millions
Addus Homecare Corporation-4.77%$ -4.767 millions
Idexx Laboratories Inc-5.05%$ -5.054 millions
Hca Healthcare Inc -7.28%$ -7.278 millions
National Research Corporation-7.51%$ -7.506 millions
Amgen Inc -10.33%$ -10.328 millions
Organon and Co -11.90%$ -11.899 millions
Regeneron Pharmaceuticals Inc -12.71%$ -12.706 millions
Intuitive Surgical Inc -15.12%$ -15.119 millions
Apollo Medical Holdings Inc -16.50%$ -16.496 millions
Encompass Health Corporation-17.09%$ -17.093 millions
Molecular Templates Inc -19.30%$ -19.296 millions
Royalty Pharma Plc-19.43%$ -19.434 millions
Natus Medical Inc-20.58%$ -20.576 millions
Fulgent Genetics Inc -23.49%$ -23.486 millions
Quest Diagnostics Inc-23.88%$ -23.878 millions
Fonar Corporation-24.12%$ -24.122 millions
Hologic Inc-26.49%$ -26.488 millions
Integra Lifesciences Holdings Corp-27.52%$ -27.521 millions
Universal Health Services Inc -27.77%$ -27.765 millions
National Healthcare Corp-27.97%$ -27.966 millions
Incyte Corp-29.03%$ -29.033 millions
Davita Inc -29.44%$ -29.439 millions
Reynolds Consumer Products Inc -29.73%$ -29.730 millions
Semler Scientific inc -31.11%$ -31.105 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

NEW's Profile

Stock Price

NEW's Financials

Business Description

Fundamentals

Charts & Quotes

NEW's News

Suppliers

NEW's Competitors

Customers & Markets

Economic Indicators

NEW's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071